|
1951 |
ICER issues draft report on rheumatoid arthritis treatments
Enthalten in PharmacoEconomics & outcomes news Bd. 770, 28.1.2017, Nr. 1, date:1.2017: 1
|
|
|
|
1952 |
ICER publishes draft scoping document on osteoporosis drugs
Enthalten in PharmacoEconomics & outcomes news Bd. 768, 17.12.2016, Nr. 1, date:12.2016: 3
|
|
|
|
1953 |
ICER releases final report on rheumatoid arthritis treatments
Enthalten in PharmacoEconomics & outcomes news Bd. 776, 22.4.2017, Nr. 1, date:4.2017: 35
|
|
|
|
1954 |
ICER review finds abaloparatide and teriparatide too costly
Enthalten in PharmacoEconomics & outcomes news Bd. 781, 1.7.2017, Nr. 1, date:7.2017: 4
|
|
|
|
1955 |
ICER says evidence on anabolic agents for osteoporosis inadequate
Enthalten in PharmacoEconomics & outcomes news Bd. 783, 29.7.2017, Nr. 1, date:7.2017: 4
|
|
|
|
1956 |
Identification of a novel autoantibody against self-vimentin specific in secondary Sjögren’s syndrome
Enthalten in Arthritis Research & Therapy Bd. 20, 12.2.2018, Nr. 1, date:12.2018: 1-8
|
|
|
|
1957 |
Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy
Enthalten in Arthritis Research & Therapy Bd. 19, 20.7.2017, Nr. 1, date:12.2017: 1-10
|
|
|
|
1958 |
Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms
Enthalten in Clinical reviews in allergy & immunology Bd. 52, 1.10.2015, Nr. 1, date:2.2017: 34-44
|
|
|
|
1959 |
‘If it’s a medical issue I would have covered it by now’: learning about fibromyalgia through the hidden curriculum: a qualitative study
Enthalten in BMC medical education Bd. 17, 12.9.2017, Nr. 1, date:12.2017: 1-9
|
|
|
|
1960 |
IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
Enthalten in Arthritis Research & Therapy Bd. 19, 15.6.2017, Nr. 1, date:12.2017: 1-12
|
|
Administration
